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AdenosineInosine (INO) has an anticonvulsant effect against seizures induced by antagonists of GABAergic system. Qui-
nolinic acid (QA) is an agonist NMDA receptors implicated in the neurobiology of seizures. In the present
study, we investigated the anticonvulsant effect of intracerebroventricular (i.c.v.) INO administration against
QA-induced seizures in adult mice. We also investigated whether the benzodiazepines (BZ) or adenosine
(ADO) receptors were involved in the INO effects. Animals were pretreated with an i.c.v. injection of either
vehicle or INO before an i.c.v. administration of 4 μl QA (36.8 nmol). All animals pretreated with vehicle fol-
lowed by QA presented seizures. INO protected against QA-induced seizures in a time and dose dependent
manner (up to 60% at 400 nmol, 5 min before QA injection). Diazepam (DZ) and ADO (i.c.v.) also exhibited
anticonvulsant effect against QA induced seizures. Additionally, i.p. administration of either ﬂumazenil, a
BZ receptor antagonist, or caffeine, an ADO receptor antagonist, did not change the anticonvulsant potency
of INO i.c.v. injection, but completely abolished the DZ and ADO anticonvulsant effects, respectively. In con-
clusion, this study demonstrated that INO exert anticonvulsant effect against hyperactivity of the glutamater-
gic system independently of BZ or ADO receptors activation.benzodiazepines; ADO, adeno-
rebral spinal ﬂuid; i.c.v., intra-
neal; PTZ, pentylenetetrazol;
saline; NMDA, N-Methyl-D-
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The purinergic system including adenine, guanine and hypoxan-
thine, and their respectively nucleosides and nucleotides, has an im-
portant role in the modulation of central nervous system (CNS)
activity (Abbracchio et al., 2009; Hasko et al., 2004; Schmidt et al.,
2007; Schmidt and Souza, 2010). Several works have reported that
the cerebral spinal ﬂuid (CSF) levels of purine nucleosides (adeno-
sine, guanosine and inosine) are augmented after a single seizure ep-
isode (Dunwiddie and Masino, 2001; Latini and Pedata, 2001; Lewin
and Bleck, 1981; Oses et al., 2004; Winn et al., 1980). Most of these
studies suggest that purine nucleosides have an important role in ter-
minated seizures.The potential anticonvulsant effect of inosine (INO) began to be inves-
tigated in the late 70's, and early 80's (Lewin and Bleck, 1985; Marangos
et al., 1981a, 1981c; Skolnick et al., 1979). It was demonstrated that intra-
cerebroventricular (i.c.v) (Skolnick et al., 1979) and subcutaneous (s.c.)
(Lewin and Bleck, 1985) INO injection was able to increase the latency
of pentylenetetrazol (PTZ)-induced seizure in mice. Additionally, the
threshold for seizures induced by both, bicuculline and picrotoxin were
signiﬁcantly raised after INO s.c. administration (Lewin and Bleck,
1985). To note, PTZ, bicuculline and picrotoxin are inhibitors of the
GABAergic complex receptor GABA-A, which contains binding sites for
GABA, barbiturates, benzodiazepines (BZ), picrotoxin, and neurosteroids
(McKernan and Whiting, 1996). GABA is recognized as the principal in-
hibitory neurotransmitter in the CNS and administration of GABA ago-
nists is able to suppresse seizures (Treiman, 2001).
Several studies have proposed that INO exerts its anticonvulsant
effects by acting on BZ binding sites in GABA-A receptors (BZ recep-
tors). BZ are classical anticonvulsants, commonly used in the clinical
practice, BZ increase the binding of GABA to GABA-A receptors, en-
hancing GABA-mediated inhibition (Treiman, 2001). INO competi-
tively displaces the binding of diazepam (DZ – a classical BZ
receptors ligand) to CNS cell membrane (Asano and Spector, 1979;
MacDonald et al., 1979; Marangos et al., 1981b, 1981c).
Recent reports showed that INO can also bind and activate adenosine
(ADO) receptors (Hasko et al., 2004). The anticonvulsant potential of ADO
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and Faull, 1988; Fedele et al., 2006; Fredholm et al., 2005; Tomé et al.,
2010; Young and Dragunow, 1994). ADO acts on different receptors in
the brain (A1, A2A, A2BandA3). INOactivates A1 receptors that exhibited
an anticonvulsant effect. However, to our knowledge, the hypothesis that
the anticonvulsant effect of INO may involve adenosinergic system was
never investigated.
Quinolinic acid (QA), an endogenous metabolite of tryptophan,
may be involved in the pathogenesis of various CNS disorders includ-
ing epilepsy (Heyes et al., 1990; Stone, 2001). QA is a well know
NMDA agonist (Stone, 1993) and, stimulating synaptosomal gluta-
mate release(Tavares et al., 2005), increasing glutamate uptake by
synaptic vesicles (Tavares et al., 2008) and inhibiting glutamate up-
take by astrocytes (Tavares et al., 2002), over stimulates the glutama-
tergic system. QA has been proposed to be a useful model of acute
seizures in rodents (Schmidt et al., 2007; Schmidt and Souza, 2010).
The aim of the present study was to investigate the anticonvulsant
potential of INO i.c.v. injection in a mouse model of acute seizures in-
duced by QA. Attempts have been made to investigate some of the
possible mechanisms underlying the anticonvulsant action of INO.
2. Materials and methods
2.1. Animals
Male adult Swiss albino mice (35–45 g) were kept on a 12 h light/
dark cycle (light on at 7:00 AM) at temperature of 22±1 °C, housed
in plastic cages with tap water and commercial food ad libitum. All
procedures were carried out according to the Brazilian Society for
Neuroscience and Behavior's recommendations for animal care and
the EC Directive 86/609/EEC for animal experiments, designed to
minimize the suffering and the number of animals used. All behavior-
al procedures were conducted between 3:00 and 6:00 PM. Each ani-
mal was used only once.
2.2. Chemicals
Inosine (INO), adenosine (ADO), caffeine (CAF), ﬂumazenil (FLU)
and diazepam (DZ) were purchased from Sigma (St. Louis, MO,
USA). The anesthetic sodium thiopental was obtained from Cristália
(Itapira, SP, Brazil). All others chemicals of analytical grade were
from standard suppliers. INO, ADO and CAF were dissolved in phos-
phate buffer saline (PBS, pH=7.4) containing (in mM): Na2HPO4
7.7, NaH2PO4 2.7 and NaCl 154. DZ and FLU were dissolved in PBS
plus 20% Tween 80 (PBS+Tween).
2.3. Surgical procedure
Surgery and i.c.v. infusion techniques were adapted from Schmidt
et al., 2000 (Schmidt et al., 2000). Animals were anesthetized with so-
dium thiopental (60 mg/kg, 10 ml/kg, i.p.). In a stereotaxic apparatus,
the skin of the skull was removed, and an i.c.v. guide cannula for infu-
sion was implanted. Stereotaxic coordinates were 1.5 mm posterior
to bregma, 1 mm right of the midline. The guide cannula was
implanted 1.7 mm ventral to the superior surface of the skull and
ﬁxed with jeweler's acrylic cement. Experiments were performed
48 h after surgery. I.c.v. treatments were performed with a 30-gauge
cannula, which was ﬁtted into the guide cannula and connected by
a polyethylene tube to a micro syringe. The tip of the infusion cannula
protruded 1 mm beyond the guide cannula, aiming the right lateral
brain ventricle.
2.4. QA-induced seizures
An i.c.v. QA infusion of 9.2 mM (4 μl), the lowest dose that cause
seizures in all animals, was performed in the study group. The controlgroup received 4 μl of vehicle. Mice were observed for 10 min in Plex-
iglas chambers to detect tonic–clonic seizures lasting more than 5 s.
Latency and duration of seizures, and mortality after seizure were
also evaluated. We considered protection against seizure when the
animals did not present seizures in 10 min. After the experiments,
the dye methylene blue (4 μl) was injected through the cannula to
identify the site of injection. Animals without the dye in the lateral
brain ventricle were discarded (Schmidt et al., 2000).
2.5. Treatments
We performed i.c.v. administration of INO, DZ (agonist of BZ) and
ADO and intraperitoneal (i.p.) administration of FLU (antagonist of
BZ) and CAF (10 mg/kg – antagonist of A1 and A2a ADO receptors
(Botton, et al. 2010; Cunha, et al. 2008).
The dose of 8 nmol DZ was chosen because of the maximal con-
centration to be dissolved in PBS+Tween, and the ability to promote
anticonvulsant effect similar to INO against QA-induced seizures. The
dose of FLU was based on previous studies showing the antagonistic
effect of FLU against DZ anticonvulsant activity (Moreau et al., 1989).
2.5.1. Treatment 1
Mice received either 4 μl i.c.v. infusion of 100–400 nmol of INO
(n=12–15 per group), or 4 μl i.c.v. infusion of vehicle (PBS) (control
group; n=12) 5 min before QA injection. We could not use higher
doses of INO because of its poor solubility.
2.5.2. Treatment 2
Mice received either 4 μl i.c.v. infusion of 400 nmol of INO
(n=12–15 per group), or 4 μl i.c.v. infusion of vehicle (PBS) (control
group; n=12–15). 1–10 min before QA injection.
2.5.3. Treatment 3
Mice received i.p. injection of either FLU (10 mg/kg) or PBS+
Tween (10 ml/kg; control group). After 15 min, 4 μl i.c.v. injection of
vehicle (PBS+Tween) or INO (400 nmol) or DZ (8 nmol) was per-
formed and 5 min later seizures were induced by QA administration
(n=12–15).
2.6. Treatment 4
Mice received i.p. injection of either CAF (10 mg/kg) or PBS
(10 ml/kg; control group). After 15 min, 4 μl i.c.v. injection of vehicle
(PBS) or INO (400 nmol) or ADO (400 nmol) was performed and
5 min later seizures were induced by QA administration (n=10–16).
2.7. Statistical analysis
Statistical analysis between groups was performed by the Fisher's
exact test to evaluate the presence of seizures and death. We used
Fischer's exact test instead of chi square test because some of the
values in some categories were less than 5. Latency and duration of
seizures were evaluated by ANOVA plus Duncan test. All results
with Pb0.05 were considered signiﬁcant. The results were reported
as mean±SE.
3. Results
QA (i.c.v) induced seizures in all animals of control groups. PBS
and/or PBS+Tween i.c.v. did not evoke any seizure by themselves.
The latency and duration of the tonic–clonic seizures of control
groups were 24.2±6 s and 20.9±5 s, respectively.
Fig. 1 shows that INO pretreatment protected mice against QA-
induced seizures. The anticonvulsant effect was dose-dependent (A)
and varied with the time of administration before QA (B). The strongest
Fig. 1. Effect of dose (A) and pretreatment time (B) of INO against QA-induced seizures.
A – Different doses of INO were administered i.c.v. 5 min before QA administration.
B – INO 400 nmol were administrated i.c.v at different times before QA-induced seizures.
After QAadministration,micewere observed during 10 min for the occurrence of seizures.
n=12–15 animals per group. P≤0.05 (Fisher's exact test). * Different from control group.
Fig. 3. CAF effect on INO or ADO anticonvulsant potential against QA-induced seizures.
CAF or vehicle (PBS) was i.p. injected 15 min before INO (400 nmol) or ADO
(400 nmol) or vehicle i.c.v. administration. Seizures were induced by i.c.v. QA infusion
5 min after INO or ADO or vehicle infusion and mice were observed for the occurrence
of seizures; n=10–16 per group. *P≤0.05 (Fisher's exact test), as compared to control,
CAF+Veh and CAF+ADO groups.
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with the administration of 400 nmol INO, 3 min before QA infusion.
Fig. 2 shows that DZ (8 nmol, i.c.v.), like INO (400 nmol, i.c.v.),
partially prevented QA-induced seizures, while FLU (10 mg/kg, i.p.)
had no effect. Moreover, FLU pretreatment (10 mg/kg, i.p., 15 min be-
fore INO or DZ injection) did not alter the anticonvulsant effect of
INO, but abolished the anticonvulsant effect of DZ.
Fig. 3 shows that ADO (400 nmol, i.c.v.), like INO (400 nmol, i.c.v.),
partially prevented QA-induced seizures, while CAF (10 mg/kg, i.p.)Fig. 2. FLU effect on INO or DZ anticonvulsant potential against QA-induced seizures.
FLU or vehicle (PBS+Tween) was i.p. injected 15 min before INO (400 nmol) or DZ
(8 nmol) or vehicle i.c.v. administration. Seizures were induced by i.c.v. QA infusion
5 min after INO or DZ or vehicle infusion and mice were observed for the occurrence
of seizures; n=12–15 per group. *P≤0.05 (Fisher's exact test), as compared to control,
FLU+Veh and FLU+DZ groups.had no effect. Additionally, CAF pretreatment (10 mg/kg, i.p., 15 min
before INO or DZ injection) did not modify the anticonvulsant effect
of INO, but abolished the anticonvulsant effect of ADO.
Of note, none of the drugs tested here (INO, ADO, DZ, FLU or CAF)
changed the pattern of seizures (onset, severity or duration). Addi-
tionally, we did not observe any sedative effects after i.c.v. injection
of INO, ADO or DZ, nor hyper locomotion activity after i.p. administra-
tion of CAF. Moreover, no remarkable behavior was observed after ad-
ministration of the drugs here used.4. Discussion
The results of the present study clearly demonstrate an anticon-
vulsant effect of INO against QA-induced seizures in adult mice. To
our knowledge, these results are the ﬁrst evidence that INO is anticon-
vulsant against hyperactivation of the glutamatergic system in the
CNS. The anticonvulsant effect of INO was previously demonstrated in
models of acute seizures based on inhibition of GABA-A receptor
complex. It is noteworthy that many different animal models may
reﬂect a diversity of seizures etiology (Siniatchkin and Koepp, 2009).
Thus, our results expand the prophylactic anticonvulsant potential of
INO to another mechanism involved on seizures etiology.
Here we demonstrated that INO exhibited an anticonvulsant effect
by central administration. Moreover, this effect (1) is dose dependent,
(2) is similar to ADO (a well know purine with anticonvulsant effect),
and (3) displays a narrow prophylactic proﬁle (since it only begins to af-
fect seizures when applied 3 min before triggering the seizures and it is
no longer active when applied 10 min before triggering the seizures).
Our results suggest that the anticonvulsant activity of INO may act
more against seizures evoked by hyperexcitation than those evoked
by decreasing the inhibitory tonus of the CNS. The anticonvulsant ef-
fect of INO on models of acute seizures induced by QA- and PTZ were
very similar regarding the dose and time of INO infusion. However,
the seizure behaviors were completely blocked by INO when seizures
were induced by QA infusion while only the latency to seizure were
increased in the PTZ model (Skolnick et al., 1979).
To our knowledge, only few studies have investigated INO effects on
excitatory synaptic transmission in brain circuits. Noteworthy, Shen et al.
(2005) have demonstrated that microinjection of INO reversibly
antagonized electrophysiological excitation by glutamate in cerebral cor-
tical neurons. Additionally, it was already demonstrated that INO was
also able to inhibit excitability in cultured spinal neurons (MacDonald
et al., 1979). Moreover, INO was able to inhibit Purkinje cell activity
(Bold et al., 1985). These studies support the hypothesis that INO may
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implicated in the anticonvulsant effect. However, until nownone speciﬁc
receptor for INO has been identiﬁed on the CNS cell membrane.
Several studies have proposed that INO effects could bemediated by
activation of BZ receptors based upon in vitro evidences that INO is able
to displace BZ agonists binding to the CNS cell membrane (Marangos
et al., 1979; Marangos et al., 1981c; Skolnick et al., 1979). In the present
study, INO anticonvulsant effect did not seem to bemediated by activa-
tion of BZ receptor, since FLU did not block INO effect while completely
abolished the DZ anticonvulsant action. To our knowledge, our study
was the ﬁrst to investigate whether a BZ antagonist could be able to
block INO effect.
The anticonvulsant effect of INO could also be mediated by activa-
tion of ADO receptors. Recently, it was recognized that INO can also
binds directly to A1, the main ADO receptor involved with the ADO an-
ticonvulsant effect (Avsar and Empson, 2004; Dragunow and Faull,
1988; Fedele et al., 2006; Young and Dragunow, 1994). However, we
could not conﬁrm this hypothesis with our present results since CAF
did not alter INO, but disrupted ADO anticonvulsant effect.
Taken altogether, neither BZ nor ADO receptors seems to be in-
volved with the anticonvulsant effect reported here, suggesting that
INO may exhibit an independently mechanism of action. Importantly,
there was no attempt in the present work to explore an additive an-
ticonvulsant effect of INO administration by activation of BZ and/or
ADO receptors. This point should be explored in future works.
Our group has been studying for a long time the potential anticon-
vulsant effect of guanine based purines (Schmidt and Souza, 2010).
We have previously demonstrated that GTP, GDP and GMP, and the
nucleoside guanosine (GUO) present anticonvulsant effect against
QA-induced seizures. We have reported that the anticonvulsant effect
of the guanine based nucleotides depends on its conversion to GUO
(Soares et al., 2004). Since GUO and INO have similar molecular struc-
tures and they share several cellular metabolic pathways, we can
speculate that INO anticonvulsant effect may involve pathways also
recruited by guanosine. Searching for neurochemical parameters in-
volved in the GUO effects, we have demonstrated that GUO stimulates
astrocytic glutamate uptake, which may be involved with its anticon-
vulsant action (Frizzo et al., 2003, 2001, 2005). However, there are no
evidences that INO could modulate astrocytic glutamate uptake. So,
further studies are necessary to clarify this hypothesis.
In summary, to our knowledge, this is the ﬁrst study reporting the
anticonvulsant effect of INO against QA induced seizures. Here we
reported the potential prophylactic effect of INO against hyperactiva-
tion of the glutamatergic system. Further studies will be required to
deﬁne the mechanisms of INO to control seizure activity and to inves-
tigate its potential therapeutic effect.
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